Coverart for item
The Resource New therapeutic agents in thrombosis and thrombolysis, edited by Jane E. Freedman, Joseph Loscalzo, (electronic book)

New therapeutic agents in thrombosis and thrombolysis, edited by Jane E. Freedman, Joseph Loscalzo, (electronic book)

Label
New therapeutic agents in thrombosis and thrombolysis
Title
New therapeutic agents in thrombosis and thrombolysis
Statement of responsibility
edited by Jane E. Freedman, Joseph Loscalzo
Contributor
Subject
Language
eng
Summary
An essential text for cardiologists, hematologists, and pharmacologists, this third edition is a resource on current agent development technology for treating cardiovascular and thromboembolic diseases. It covers advances in scientific discovery, the growing number of patients and indications for antithrombotics, and more.
Member of
Cataloging source
DNLM/DLC
Dewey number
616.13506
Illustrations
illustrations
Index
index present
LC call number
RC694.3
LC item number
.N49 2009
Literary form
non fiction
Nature of contents
bibliography
http://library.link/vocab/relatedWorkOrContributorName
  • Freedman, Jane E.
  • Loscalzo, Joseph.
Series statement
Fundamental and clinical cardiology
Series volume
65
http://library.link/vocab/subjectName
  • Thrombolytic therapy
  • Fibrinolytic agents
  • Thrombosis
  • Thrombolytic Therapy
  • Fibrinolytic Agents
  • Hemostasis
  • Platelet Aggregation Inhibitors
  • Thrombosis
Summary expansion
As the number of patients with thrombosis and thrombolysis increases, there is a critical need for clinicians to learn the latest scientific discoveries and treatment options. This timely Third Edition is a comprehensive text for cardiologists, hematologists, and pharmacologists in need of a resource on current agent development technology for treating cardiovascular and thromboembolic diseases. New to the Third Edition: a thorough examination of all the agents involved in treating thrombosis chapters on biomarkers, testing, and pharmacogenomics key topics, including new targets for antithrombotics, the development of novel classes of platelet inhibitors, new thrombolytic therapies, and evolving clinical uses of thrombolytics for ischemic stroke and venous thrombosis the hemostatic and thrombotic pathways
Label
New therapeutic agents in thrombosis and thrombolysis, edited by Jane E. Freedman, Joseph Loscalzo, (electronic book)
Instantiates
Publication
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier MARC source
rdacarrier
Content category
text
Content type MARC source
rdacontent
Contents
<P><STRONG>OVERVIEW OF THE INVESTIGATION AND REGULATION AND THROMBOSIS<BR></STRONG><I>Jane EFreedman<BR></I>Overview of Hemostasis and Fibrinolysis, <I>Andrew ISchafer</I><BR>Overview of Platelet-Dependent Thrombosis, <I>Jane EFreedman, Price Blair, and Joseph Loscalzo</I><BR>Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents, <I>Robert PGiugliano</I><BR>Pharmacogenomics and Warfarin Anticoagulation, <I>Melkon Hacobian and Samuel ZGoldhaber</I><BR>Pharmacogenomics of Platelet Inhibitors, <I>Srikanth Nagalla, Suzanne MLeal, and Paul FBray</I><BR>The Effects of Antiplatelet, Antithrombotic, and Thrombolytic Agents on Inflammation and Circulating Inflammatory Biomarkers, <I>Erdal Cavusoglu</I><BR>The Role of Platelet Function Testing in the Development of Platelet Inhibitors, <I>Alan DMichelson</I><BR>The Role of Proteomics and Transcriptomics in the Development of Antithrombotics, <I>Lisa Senzel, Dmitri VGnatenko, and Wadie FBahou<BR></I><BR><B>NEW HEPARINS, THROMBIN INHIBITORS, AND ANTITHROMBOTICS<BR></B><I>Jeffrey IWeitz<BR></I>Overview of New Anticoagulant Drugs, <I>Nahid Qushmaq and Jeffrey IWeitz</I><BR>Anticoagulants for the Treatment of Venous Thromboembolism, <I>Sam Schulman</I><BR>Anticoagulation in Acute Coronary Syndromes, <I>Simon JMcRae and John WEikelboom</I><BR>Anticoagulation in Pregnancy, <I>Shannon MBates</I><BR>Anticoagulants in Cancer, <I>Edward NLibby and Agnes YLee</I><BR>Anticoagulation in Children, <I>Paul TMonagle and Anthony K.CChan</I><BR>New Heparins: Synthetic Pentasaccharides, <I>Pieter WKamphuisen and Harry RBller</I><BR>Treatment of Heparin-Induced Thrombocytopenia, <I>Theodore EWarkentin</I><BR>Emerging Links Between Thrombosis, Inflammation, and Angiogenesis: Key Role of Heparin and Low-Molecular-Weight Heparins, <I>Shaker AMousa</I><BR>Oral Direct Factor Xa Inhibitors, <I>Alexander GGTurpie</I><BR>Direct Thrombin Inhibitors, <I>Menaka Pai and Mark ACrowther</I><BR>Modulators of the Protein C Pathway, <I>Charles TEsmon</I><BR>Factor IXa Inhibitors, <I>Richard CBecker, Mark Chan, Emily LHoward, Kristian CDBecker, and Christopher PRusconi<BR></I>Contact-Activation Pathways as Targets for New Anticoagulants, <I>David Gailani, Thomas Renne', and Andras Gruber<BR></I><BR><B>NEW ANTIPLATELET AGENTS<BR></B><I>Robert PGiugliano<BR></I>Overview of Antiplatelet Therapy, <I>Shaker AMousa, James TWillerson, and Robert PGiugliano</I><BR>Markers of Platelet Function, <I>Udaya STantry and Paul AGurbel</I><BR>Intravenous Glycoprotein IIb/IIIa Antagonists, <I>Jason NKatz and Robert AHarrington</I><BR>Inhibitors of Platelet Adhesion: VWF-GPb/IX and Collagen-GPVI<BR>Inhibitors, <I>Robert GSchaub</I><BR>Three Generations of Thienopyridines: Ticlopidine, Clopidogrel, and Prasugrel, <I>Stephen DWiviott and Elliott MAntman<BR></I>Direct PYAntagonists, <I>Marco Cattaneo</I><BR>Nitric Oxide Donors as Platelet Inhibitors, <I>Lina Badimon and Gemma Vilahur</I><BR>The Interrelationship of Thrombin and Platelets-The Protease-Activated Receptor-, <I>Rohit Bhatheja and David JMoliterno<BR></I>Other Antiplatelet Agents, <I>Catherine McGorrian and Sonia SAnand<BR></I>The Combination of Anticoagulants and Platelet Inhibitors Postcoronary Stent Implantation, <I>Hussam Hamdalla and Steven RSteinhubl<BR><BR></I><B>NEW THROMBOLYTIC AGENTS AND INDICATIONS<BR></B><I>HRoger Lijnen<BR></I>Overview of Established and New Thrombolytics, <I>HRoger Lijnen</I><BR>Thrombolysis of Deep Vein Thrombosis, <I>Peter Verhamme, Raymond Verhaeghe, and Geert Maleux</I><BR>Thrombolysis for Acute Pulmonary Embolism, <I>Gregory Piazza and Samuel ZGoldhaber</I><BR>Acute Thrombolysis in Ischemic Cerebrovascular Disease, <I>Gregory Jdel Zoppo</I><BR>Fibrinolysis for Acute Myocardial Infarction, <I>Cheuk-Kit Wong and Harvey DWhite</I><BR>Epilogue: The Evolution of Therapeutic Management of Thrombotic and Cardiovascular Disease, <I>Jane EFreedman and Joseph Loscalzo</I><BR>Index<BR></P>
Control code
AH24914309
Edition
3rd ed.
Extent
xv, 690 p.
Form of item
electronic
Governing access note
After 5 minutes Preview, click on &#x32;Request Access&#x33;, fill in a form with your details. If triggered, the book will be loaned and tied to the one user for 1 week, during which time users can read or download as they choose. 4th user request triggers auto-purchase
Isbn
9781420069242
Lccn
2008042440
Media category
computer
Media MARC source
rdamedia
Specific material designation
remote
Label
New therapeutic agents in thrombosis and thrombolysis, edited by Jane E. Freedman, Joseph Loscalzo, (electronic book)
Publication
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier MARC source
rdacarrier
Content category
text
Content type MARC source
rdacontent
Contents
<P><STRONG>OVERVIEW OF THE INVESTIGATION AND REGULATION AND THROMBOSIS<BR></STRONG><I>Jane EFreedman<BR></I>Overview of Hemostasis and Fibrinolysis, <I>Andrew ISchafer</I><BR>Overview of Platelet-Dependent Thrombosis, <I>Jane EFreedman, Price Blair, and Joseph Loscalzo</I><BR>Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents, <I>Robert PGiugliano</I><BR>Pharmacogenomics and Warfarin Anticoagulation, <I>Melkon Hacobian and Samuel ZGoldhaber</I><BR>Pharmacogenomics of Platelet Inhibitors, <I>Srikanth Nagalla, Suzanne MLeal, and Paul FBray</I><BR>The Effects of Antiplatelet, Antithrombotic, and Thrombolytic Agents on Inflammation and Circulating Inflammatory Biomarkers, <I>Erdal Cavusoglu</I><BR>The Role of Platelet Function Testing in the Development of Platelet Inhibitors, <I>Alan DMichelson</I><BR>The Role of Proteomics and Transcriptomics in the Development of Antithrombotics, <I>Lisa Senzel, Dmitri VGnatenko, and Wadie FBahou<BR></I><BR><B>NEW HEPARINS, THROMBIN INHIBITORS, AND ANTITHROMBOTICS<BR></B><I>Jeffrey IWeitz<BR></I>Overview of New Anticoagulant Drugs, <I>Nahid Qushmaq and Jeffrey IWeitz</I><BR>Anticoagulants for the Treatment of Venous Thromboembolism, <I>Sam Schulman</I><BR>Anticoagulation in Acute Coronary Syndromes, <I>Simon JMcRae and John WEikelboom</I><BR>Anticoagulation in Pregnancy, <I>Shannon MBates</I><BR>Anticoagulants in Cancer, <I>Edward NLibby and Agnes YLee</I><BR>Anticoagulation in Children, <I>Paul TMonagle and Anthony K.CChan</I><BR>New Heparins: Synthetic Pentasaccharides, <I>Pieter WKamphuisen and Harry RBller</I><BR>Treatment of Heparin-Induced Thrombocytopenia, <I>Theodore EWarkentin</I><BR>Emerging Links Between Thrombosis, Inflammation, and Angiogenesis: Key Role of Heparin and Low-Molecular-Weight Heparins, <I>Shaker AMousa</I><BR>Oral Direct Factor Xa Inhibitors, <I>Alexander GGTurpie</I><BR>Direct Thrombin Inhibitors, <I>Menaka Pai and Mark ACrowther</I><BR>Modulators of the Protein C Pathway, <I>Charles TEsmon</I><BR>Factor IXa Inhibitors, <I>Richard CBecker, Mark Chan, Emily LHoward, Kristian CDBecker, and Christopher PRusconi<BR></I>Contact-Activation Pathways as Targets for New Anticoagulants, <I>David Gailani, Thomas Renne', and Andras Gruber<BR></I><BR><B>NEW ANTIPLATELET AGENTS<BR></B><I>Robert PGiugliano<BR></I>Overview of Antiplatelet Therapy, <I>Shaker AMousa, James TWillerson, and Robert PGiugliano</I><BR>Markers of Platelet Function, <I>Udaya STantry and Paul AGurbel</I><BR>Intravenous Glycoprotein IIb/IIIa Antagonists, <I>Jason NKatz and Robert AHarrington</I><BR>Inhibitors of Platelet Adhesion: VWF-GPb/IX and Collagen-GPVI<BR>Inhibitors, <I>Robert GSchaub</I><BR>Three Generations of Thienopyridines: Ticlopidine, Clopidogrel, and Prasugrel, <I>Stephen DWiviott and Elliott MAntman<BR></I>Direct PYAntagonists, <I>Marco Cattaneo</I><BR>Nitric Oxide Donors as Platelet Inhibitors, <I>Lina Badimon and Gemma Vilahur</I><BR>The Interrelationship of Thrombin and Platelets-The Protease-Activated Receptor-, <I>Rohit Bhatheja and David JMoliterno<BR></I>Other Antiplatelet Agents, <I>Catherine McGorrian and Sonia SAnand<BR></I>The Combination of Anticoagulants and Platelet Inhibitors Postcoronary Stent Implantation, <I>Hussam Hamdalla and Steven RSteinhubl<BR><BR></I><B>NEW THROMBOLYTIC AGENTS AND INDICATIONS<BR></B><I>HRoger Lijnen<BR></I>Overview of Established and New Thrombolytics, <I>HRoger Lijnen</I><BR>Thrombolysis of Deep Vein Thrombosis, <I>Peter Verhamme, Raymond Verhaeghe, and Geert Maleux</I><BR>Thrombolysis for Acute Pulmonary Embolism, <I>Gregory Piazza and Samuel ZGoldhaber</I><BR>Acute Thrombolysis in Ischemic Cerebrovascular Disease, <I>Gregory Jdel Zoppo</I><BR>Fibrinolysis for Acute Myocardial Infarction, <I>Cheuk-Kit Wong and Harvey DWhite</I><BR>Epilogue: The Evolution of Therapeutic Management of Thrombotic and Cardiovascular Disease, <I>Jane EFreedman and Joseph Loscalzo</I><BR>Index<BR></P>
Control code
AH24914309
Edition
3rd ed.
Extent
xv, 690 p.
Form of item
electronic
Governing access note
After 5 minutes Preview, click on &#x32;Request Access&#x33;, fill in a form with your details. If triggered, the book will be loaned and tied to the one user for 1 week, during which time users can read or download as they choose. 4th user request triggers auto-purchase
Isbn
9781420069242
Lccn
2008042440
Media category
computer
Media MARC source
rdamedia
Specific material designation
remote

Library Locations

Processing Feedback ...